Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT05162066
PHASE2

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

Sponsor: BioCryst Pharmaceuticals

View on ClinicalTrials.gov

Summary

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Official title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

2

Start Date

2022-02-18

Completion Date

2022-09-23

Last Updated

2026-11-10

Healthy Volunteers

No

Interventions

DRUG

BCX9930

Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Locations (11)

Investigative Site

Poitiers, France

Investigative Site

Toulouse, France

Investigative Site

Bari, Italy

Investigative Site

Bergamo, Italy

Investigative Site

Brescia, Italy

Investigative Site

Turin, Italy

Investigative Site #1

Barcelona, Spain

Investigative Site #2

Barcelona, Spain

Investigative Site #1

Madrid, Spain

Investigative Site #2

Madrid, Spain

Investigative Site

Oxford, United Kingdom